Related Experiment Video
Updated: Mar 20, 2026

Microscopic Electric Rotary Grinding of Plaques Combined with Graft Repair in the Management of Peyronie's Disease
Published on: March 15, 2024
Evidence-Based Management Guidelines on Peyronie's Disease.
Eric Chung1, David Ralph2, Ates Kagioglu3
1Department of Urology, University of Queensland, Princess Alexandra Hospital, Brisbane, QLD, Australia; AndroUrology Centre, St. Andrew's War Memorial Hospital, Brisbane, QLD, Australia.
Despite advances, Peyronie
Area of Science:
- Urology
- Sexual Medicine
Background:
- Peyronie's Disease (PD) remains incompletely understood despite recent therapeutic progress.
- Existing knowledge gaps hinder comprehensive clinical management and research.
- A need exists for updated clinical guidelines based on current evidence.
Purpose of the Study:
- To establish a clinical framework for evidence-based management of Peyronie's Disease.
- To provide key guideline statements for clinicians treating PD.
- To update and expand upon previous international consultation guidelines.
Main Methods:
- Systematic literature search up to June 2015 for PD-related articles.
- Assessment of evidence levels (Oxford Centre for Evidence-Based Medicine) for guideline grading.
- Consensus guideline development by a panel based on highest available evidence, acknowledging limitations in surgical trial data.
Main Results:
- Established consensus guideline statements for the Fourth International Consultation on Sexual Medicine.
- Developed seven new summary recommendations beyond existing Third International Consultation guidelines.
- Guideline statements often reflect clinical principles or expert opinion due to limited high-level evidence for surgical interventions.
Conclusions:
- Enhanced understanding of PD's scientific basis is crucial.
- Further research is needed in pathophysiology, epidemiology, psychosocial aspects, diagnosis, and treatment.
- Continued efforts are required to improve the evidence base for PD management.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Peripheral Artery Disease III: Interprofessional Care
Atherosclerosis III: Management
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Rheumatic Heart Disease III: Medical Management

